Genmab’s Breakthrough Ovarian & Lymphoma Data Spark European Biotech Rally
Genmab’s new Phase‑2 data on Rina‑S and Epcoritamab spark a sharp EU biotech rally, promising breakthrough front‑line cancer treatments and a surge in shareholder value.
3 minutes to read